natgillin/translations-raw huggingface dataset:
Tumour assessment was based on RECIST 1.1 criteria.
Ocenjevanje tumorja je temeljilo na merilih RECIST 1.1. Datum zaključka zbiranja podatkov =
Tumour assessments were continued after treatment discontinuation in patients who discontinued treatment for reasons other than progression.
Pri bolnikih, ki so zdravljenje zaključili zaradi drugih razlogov in ne napredovanja bolezni, se je vrednotenje tumorja nadaljevalo tudi po zdravljenju.
Tumour assessments, according to the RECIST.
Vrednotenje tumorja je bilo izvedeno po kriterijih RECIST.
Tumour assessments, according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, were conducted 9 weeks after randomisation and continued every 6 weeks thereafter.
Vrednotenje tumorja na osnovi različice 1.1 kriterijev za vrednotenje odziva pri solidnih tumorjih (RECIST v1.1, Response Evaluation Criteria in Solid Tumours, version 1.1) je bilo izvedeno 9 tednov po randomizaciji, nato pa se je nadaljevalo na vsakih 6 tednov.
Tumour bleedingsa
tumorske krvavitvea
Tumour burden
Tumorsko breme
Tumour cell mobilisation in leukaemia patients
Mobilizacija tumorskih celic pri bolnikih z levkemijo
Tumour destruction leading to hole in the intestine (perforation).
predrtje črevesa zaradi razkroja tumorja
Tumour development was preceded by pneumocyte proliferation in the lung which was not observed in rats, dogs, or monkeys, indicating that a key event in lung tumour development observed in mice likely was species-specific.
Pred pojavom tumorja so zasledili proliferacijo pnevmocitov, česar pa pri podganah, psih ali opicah niso opazili, kar kaže, da je ključni dogodek pri razvoju pljučnega tumorja, ki so ga opazili pri miših, lahko vrstno specifičen.
Tumour evaluations were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 in Study A and RECIST 1.1 in Study B.
Vrednotenje tumorjev so izvajali v skladu s kriteriji za vrednotenje odziva pri solidnih tumorjih (Response Evaluation Criteria in Solid Tumors, RECIST) in sicer v študiji A po kriterijih RECIST 1.0, v študiji B pa po kriterijih RECIST 1.1.
Tumour flare reaction
Reakcija izbruha tumorja
Tumour flare reaction and tumour lysis syndrome
Reakcija izbruha tumorja in sindrom tumorske lize
Tumour flare reaction may mimic progression of disease (PD).
Reakcija izbruha tumorja lahko posnema napredovanje bolezni.
Tumour flare reaction, Squamous skin cancerˆ◊, Basal cell Carcinoma◊
reakcija izbruha tumorja
Tumour grading
gradus tumorja
Tumour haemorrhage*
krvavitev iz tumorja
Tumour haemorrhage/tumour necrosis*
krvavitev iz tumorja/nekroza tumorja
Tumour lysis syndrome
hipofosfatemija hipoalbuminemija sindrom lize tumorja
Tumour lysis syndrome
indrom razpada tumorja
Tumour lysis syndrome
indrom tumorske lize
Tumour lysis syndrome
sindrom tumorske lize
Tumour lysis syndrome (see also Data from compassionate use programme and non-pivotal studies)
sindrom tumorske lize (glejte tudi podatke iz programa sočutne uporabe (compassionate use programme) in neključnih študij)
Tumour Lysis Syndrome (TLS)
Sindrom lize tumorja (TLS – tumour lysis syndrome)
Tumour lysis syndrome (TLS)
Sindrom razpada tumorja
Tumour lysis syndrome (TLS) has been reported with Gazyvaro.
Med uporabo zdravila Gazyvaro so poročali o sindromu razpada tumorja.
Tumour lysis syndrome (TLS): Unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have happened during treatment of cancer and sometimes even without treatment.
Sindrom razpada tumorja (TLS-Tumour lysis syndrome): nenormalne koncentracije biokemijskih parametrov, ki jih povzroči hitro razpadanje rakavih celic.
Tumour lysis syndrome Hyperuricaemia
sindrom levkostaze
Tumour lysis syndrome – 7 cases (see sections 4.2 and 4.4)
Sindrom tumorske lize – 7 primerov (glejte poglavji 4.2 in 4.4)
Tumour lysis syndrome*
indrom tumorske lize
Tumour lysis syndrome*
sindrom lize tumorja
tumour lysis syndrome, cytokine release syndrome4, serum sickness
indrom lize tumorja, sindrom sproščanja citokinov4, serumska bolezen
tumour lysis syndrome, dehydration, hypoalbuminemia, hypercholesterolemia
sindrom tumorske lize, dehidracija, hipoalbuminemija, hiperholesterolemija
Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention
sindrom razpada tumorja, zastoj rasti*, hipomagneziemija*, hipofosfatemija*, hiperkaliemija*, hiperkalciemija*, hipernatriemija*, nenormalne koncentracije sečne kisline*, sladkorna bolezen*, zastajanje tekočine
Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention
sindrom tumorske lize, zastoj rasti*, hipomagneziemija*, hipofosfatemija*, hiperkaliemija*, hiperkalciemija*, hipernatriemija*, nenormalne koncentracije sečne kisline*, sladkorna bolezen*, zastajanje tekočine
Tumour lysis syndrome, hyperuricaemia
indrom razpada tumorja, hiperurikemija
tumour pain
bolečina zaradi raka
Tumour pain
tumorska bolečina
tumour pain
tumorske bolečine
tumour pain, flushing, malaise, cold syndrome,
tumorska bolečina, zardevanje, splošno slabo počutje, prehladni sindrom,
Tumour pain, Infected neoplasm
tumorska bolečina, okužba novotvorbe
Tumour pain, infected tumour
tumorska bolečina, okužen tumor,
Tumour pain, Myelodysplastic syndrome/Acute myeloid leukaemia*
bolečina zaradi tumorja, mielodisplastični sindrom/akutna mieloblastna levkemija
tumour painlack of energy, feeling weak or tired
pomanjkanje energije, občutek šibkosti ali utrujenosti,
Tumour response rate
število bolnikov delež odziva tumorja (%) 95-% IZ
Tumour response rate (%)
delež odziva tumorja (%)
Tumour response rate (%)
odzivnost tumorja (%)
Tumour response was assessed according to the revised International Working Group (IWG) for non-Hodgkin’s lymphoma (NHL) criteria.
Tumorski odgovor so ocenjevali po popravljenih kriterijih mednarodne delovne skupine (IWG - International Working Group) za ne-Hodgkinove limfome.
Tumour response was assessed at 12-week intervals.
Odgovor tumorja so ocenjevali v 12-tedenskih presledkih.
Tumour response was independent of Odomzo dose or plasma concentration in the dose range of 200 mg to 800 mg.
V okviru odmerjanja od 200 mg do 800 mg tumorski odziv ni bil odvisen od višine odmerka zdravila Odomzo oziroma od dosežene koncentracije v plazmi.
Tumour shrinkage [%]°
Skrčenje tumorja [%]°
Tumour size
0,39-0,9
Tumour size
Velikost tumorja
Tumour size was not measured directly during the clinical trial programme, but there was an indirect beneficial tumour response as shown by a 95% reduction after 12 months in median PSA for degarelix.
Med programom kliničnega preskušanja velikosti tumorja niso merili neposredno, pač pa se je posreden koristni odziv tumorja pri degareliksu po 12 mesecih pokazal s 95-odstotnim znižanjem medianega PSA.
Tumour types included were Ewing's Sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma, and rhabdomyosarcoma.
Zastopane so bile naslednje vrste tumorjev: Ewingov sarkom oz. primitivni nevroektodermalni tumor, nevroblastom, osteoblastom in rabdomiosarkom.
Tumour types included were Ewing’s Sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma, and rhabdomyosarcoma.
Vključene so bile naslednje vrste tumorjev: Ewingov sarkom/primitivni nevroektodermalni tumor, nevroblastom, osteoblastom in rabdomiosarkom.
Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site.
tumorji, ki razjedajo večje krvne žile na mestu ali v bližini mesta obsevanja;
Tumours located within 1 cm of the eyes, nose, mouth, ears or hairline were excluded.
Tumorjev, ki so se nahajali manj kot 1 cm od oči, nosu, ust, ušes ali lasišča, niso vključili.
Tumours must be inactive and you must have finished your anti-tumour treatment before you start treatment with NutropinAq. if you have complications after a major surgery (open-heart or abdominal surgery), a multiple trauma, acute respiratory failure, or similar conditions.
Tumorji morajo biti neaktivni, preden začnete zdravljenje z zdravilom NutropinAq, pa morate zaključiti zdravljenje tumorja. če imate zaplete po veliki operaciji (operacija na odprtem srcu ali v trebušni votlini), politravmo, akutno respiratorno odpoved ali podobna stanja.
tumours of the hypothalamus and pituitary gland
tumorji hipotalamusa in hipofize
tumours of the hypothalamus and pituitary gland
tumorji hipotalamusa in hipofize;
tumours of the hypothalamus or pituitary gland
tumorji hipotalamusa ali hipofize
Tumours of the hypothalamus or pituitary gland
tumorji hipotalamusa ali hipofizne žleze
tumours of the hypothalamus or pituitary gland,
tumorje hipotalamusa ali hipofize,
tumours of the hypothalamus or pituitary gland;
tumorji hipotalamusa ali hipofize
tumours of the hypothalamus or pituitary gland;
tumorji hipotalamusa ali hipofize;
Tumours of the hypothalamus orpituitary gland
tumorji hipotalamusa ali hipofizne žleze
Tumours of the ovary, breast, uterus, pituitary or hypothalamus.
tumorji jajčnikov, dojk, maternice, hipofize ali hipotalamusa,
TUNGSTEN CONTAINER
VOLFRAMOV VSEBNIK
Turbid white suspension.
Suspenzija za injiciranje Motna bela suspenzija.
Turkeys and chickens
Piščanci in purani
Turkeys only - for the treatment of infections caused by Pasteurella multocida.
Purani: zdravljenje infekcij, ki jih povzroči Pasteurella multocida.
Turkeys: do not use within 21 days of the onset of lay.
Purani: Ne uporabite prej kot 21 dni od začetka nesnosti.
Turkeys: One dose of vaccine from 1 day of age followed by second dose of vaccine 3 weeks later by coarse spray administration.
Purani: en odmerek cepiva se da s pršenjem z velikimi kaplicami živalim, starim 1 dan in več, 3 tedne kasneje mu sledi drugi odmerek cepiva.
Turn bottle upright and remove the entire syringe from the bottle.
Steklenico obrnite v pokončen položaj in v celoti odstranite brizgo iz steklenice.
Turn dose knob clockwise until it stops and the is in the dose window.
Obračajte gumb za odmerjanje v smeri urnega kazalca, dokler se ne ustavi in je v okencu za odmerjanje .
Turn dose knob clockwise until it stops at .
Obračajte gumb za odmerjanje v smeri urnega kazalca, dokler se ne ustavi na .
Turn in the direction indicated by the arrow to the unlocked position.
Obrnite v smeri puščice v odklenjen položaj.
Turn it anti-clockwise to remove it from the BIO-SET vial.
Obračajte jo v nasprotni smeri urinega kazalca, da jo odstranite od viale BIO-SET-a.
Turn it clockwise until it locks into place.
Sučite jo v smeri urinega kazalca, da se zaskoči.
Turn K the syringe with the vial upside down.
Obrnite brizgo z vialo na glavo.
Turn on mains water when all the vaccine water has been consumed.
Ko piščanci popijejo vso vodo s cepivom, odpremo sistem za napajanje.
Turn over (Notes information)
Obrnite (Opomba)
Turn over for
Za navodilo za
Turn over for injection steps
Za navodilo za injiciranje glejte hrbtno stran.
Turn over the protective cap and snap the vial D adapter onto the vial.
Obrnite zaščitni pokrovček in nataknite nastavek za vialo na vialo.
Turn over the protective cap, and snap the vial adapter onto the vial.
Obrnite zaščitni pokrovček in nataknite nastavek za vialo na vialo.
Turn over to continue…
Obrnite za nadaljevanj e ...
Turn the bottle back into an upright position before removing the syringe.
Preden izvlečete brizgo, obrnite steklenico nazaj v pokončni položaj.
Turn the bottle the right way up (figure 6A).
Obrnite steklenico pokonci (slika 6A).
Turn the bottle the right way up.
Obrnite plastenko v pravilen pokončen položaj.
Turn the bottle the right way up.
Obrnite stekleničko v pravilen pokončen položaj.
Turn the bottle updside down with the oral syringe still inserted.
Steklenico obrnite z glavo navzdol, pri čemer je peroralna brizga še vedno vstavljena.
Turn the bottle upside down and gently withdraw the required amount of Aptivus oral solution.
Steklenico obrnite navzdol in narahlo odvzemite potrebno količino peroralne raztopine zdravila Aptivus.
Turn the bottle upside down with the syringe still in place.
Plastenko z nameščeno brizgo obrnite narobe.
Turn the bottle upside down.
Obrnite stekleničko navzdol.
Turn the cap upside down (180°).
Obrnite zaporko na glavo (180°).
Turn the closed bottle upside down and shake down once before each use.
Pred vsako uporabo obrnite navzdol zaprt kapalni vsebnik in ga pretresite.
Turn the dial to number 1 (see Figure 1).
Obrnite gumb za nastavitev do številke 1 (glejte sliko 1).
Turn the dial to number 2 (see Figure 3).
Obrnite gumb za nastavitev do številke 2 (glejte sliko 3).
Turn the dial to your prescribed dose (see Figure 8).
Obrnite gumb za nastavitev na svoj predpisani odmerek (glejte sliko 8).
Turn the dosage knob until the desired dose (dose bar) is set in the display window.
Obračajte gumb za nastavitev odmerka, dokler se na okencu za prikaz odmerka ne nastavi želeni odmerek (črtica za odmerjanje).
Turn the Dose Knob backward or forward to correct the dose.
Gumb za odmerjanje vrtite nazaj ali naprej, da popravite odmerek.
Turn the dose selector to select the dose you need, as directed by your doctor or nurse.
Zavrtite izbirnik odmerka, da boste izbrali odmerek, kot vam je pokazal zdravnik ali medicinska sestra.
Turn the dose selector to select the dose you need.
Zavrtite izbirnik odmerka, da boste izbrali predpisani odmerek.
Turn the dose selector until the dose counter stops.
Vrtite izbirnik odmerka dokler se števec odmerka ne ustavi.
Turn the dose setting knob forward to dial up Turn the dose setting knob backward to correct the dose
Gumb za nastavitev odmerka obračajte naprej Gumb za nastavitev odmerka obračajte nazaj do pravilnega odmerka
Turn the dose setting knob until your intended dose shows in the Dose Feedback Window.
Obračajte gumb za nastavitev odmerka, dokler se v oknu za prikaz odmerka ne prikaže želeni odmerek.
Turn the inhaler upside down, tap the bottom and throw the empty capsule away.
Inhalator obrnite na glavo, potrkajte po spodnji strani in zavrzite prazno kapsulo.
Turn the K syringe with the vial upside down.
Obrnite brizgo z vialo na glavo.
Turn the mixing bottle upside-down together with the syringe.
Mešalno plastenko skupaj z vstavljeno brizgo obrnite na glavo.
Turn the mouthpiece back to its closed position.
Zasukajte ustnik nazaj v zaprti položaj.
TURN THE PAGE FOR MORE ADVICE
ZA DODATNE INFORMACIJE OBRNITE STRAN
Turn the page for more advice Now turn over>
Za dodatne informacije obrnite stran Obrnite stran >
Turn the page for more advice.
Za dodatne informacije obrnite stran
Turn the plunger clockwise until a slight resistance is felt (see Diagram 6).
Bat zavrtite v smeri urnega kazalca, dokler ne začutite rahlega odpora (glejte sliko 6).
Turn the pre-filled pen so that the white arrow points toward the injection site.
Pokrovček (2) Napolnjen injekcijski peresnik obrnite tako, da bela puščica kaže proti mestu injiciranja.
Turn the solvent vial upside down with the device still attached.
Obrnite vialo z vehiklom, pri tem mora biti pribor še vedno pritrjen.
Turn the solvent vial upside down with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the product vial stopper.
Obrnite vialo z vehiklom, na katero je pritrjen komplet Mix2Vial, in porinite konico prozornega adapterja naravnost navzdol skozi zamašek viale z zdravilom.
Turn the syringe and vial upside down, still in a straight line.
Injekcijsko brizgo in vialo obrnite na glavo, še vedno poravnani.
Turn the syringe and vial upside down.
Brizgo in vialo obrnite na glavo.
Turn the syringe assembly over and draw up the prescribed amount of the solution
Sklop brizge obrnite navzgor in izvlecite potrebno količino raztopine.
Turn the syringe to point upwards – this means that the solvent vial is now upside down.
Brizgo obrnite navzgor - to pomeni, da bo viala z vehiklom zdaj obrnjena na glavo.
Turn the syringe with the vial upside down.
Obrnite injekcijsko brizgo z vialo na glavo.
Turn the syringe-vial-assembly over, then withdraw plunger to redraw the dissolved medicine.
Sestavo brizge in viale obrnite navzgor, in izvlecite bat, da izvlečete raztopljeno zdravilo.
Turn the tray over and gently press the middle of the tray’s back to release the syringe into your palm.
Pretisni omot obrnite in ga na sredini z zadnje strani previdno pritisnite, da se vam bo brizga sprostila v dlan.
Turn the vial and syringe upside down
Obrnite vialo in brizgo tako, da bo viala na vrhu.
Turn the vial and the syringe upside down
Vialo in brizgo obrnite tako, da bo viala zgoraj.
Turn the vial and the syringe upside down in one hand.
Vialo in brizgo držite obrnjeno narobe v eni roki.
Turn the vial so that the stopper window is up and visible.
Vialo obrnite tako, da bo okence v zamašku obrnjeno navzgor in ga dobro vidite.
Turn the vial so that you can see the stopper gap, as shown.
Vialo obrnite tako, da vidite prazen prostor v zamašku, kot kaže slika..
Turn the vial upside down and draw up to the line mark of the syringe for injection.
Zasukajte vialo na glavo in povlecite iz nje količino do črtne oznake na brizgi za injiciranje.
Turn the vial upside down and gently draw up all the water (solvent).
Obrnite vialo navpično navzdol in previdno izvlecite vso vodo (vehikel).
Turn the vial upside down and using another sterile, disposable syringe of appropriate size (e.g.
Zgornji del viale obrnite navzdol in s pomočjo druge sterilne injekcijske brizge za enkratno uporabo primerne velikosti (npr.
Turn the vial upside down, gently draw the solution back into the syringe.
Obrnite vialo navpično navzdol in previdno potegnite raztopino nazaj v brizgo.
Turn the vial upside down, with the needle/non-vented transfer device remaining in the vial.
Vialo obrnite na glavo z iglo/neprezračevanim pripomočkom za prenos, pritrjenim na vialo.
Turn the vial upside down, with the syringe still attached.
Obrnite vialo navzdol skupaj s pritrjeno injekcijsko brizgo.
Turn the vial upside down.
Vialo obrnite navzdol.
Turn the whole thing upside down (bottle and dispenser – see picture below).
Oboje skupaj obrnite na glavo (steklenico in razdelilnik – glejte spodnjo sliko).
Turn the whole unit upright.
Steklenico in odmernik skupaj ponovno obrnite pokončno.
Turn upright and remove the oral syringe.
Plastenko spet zasukajte navzgor in izvlecite brizgo za peroralno dajanje.
Turn vial assembly and syringe upside down, so the vial is directly above the syringe.
Obrnite sestavljeno enoto z vialo in brizgo na glavo, tako da je viala neposredno nad brizgo.
turn you on your side get medical help straight away
položiti na bok, nemudoma poiskati zdravniško pomoč,
Turnhoutseweg, 30 B-2340 Beerse Belgium
Turnhoutseweg 30 B-2340 Beerse Belgija
Turoctocog alfa (human coagulation factor VIII (rDNA) is a purified protein that has 1,445 amino acids with an approximate molecular mass of 166 kDA.
Turoktokog alfa (humani koagulacijski faktor VIII (rDNA)) je prečiščen protein s 1.445 aminokislinami in približno molekulsko maso 166 kDa.
turoctocog alfa (human coagulation factor VIII (rDNA))
turoktokog alfa (humani koagulacijski faktor VIII (rDNA))
Turoctocog alfa is a B-domain truncated recombinant human coagulation factor VIII (B-domain consists of 21 amino acids of the wild type B-domain) without any other modifications in the amino acid sequence.
Turoktokog alfa je humani koagulacijski faktor VIII z odstranjeno domeno B (domena B obsega 21 aminokislin divjega tipa domene B), brez kakršnih koli drugih sprememb zaporedja aminokislin.
Turoctocog alfa is a B-domain truncated recombinant human coagulation factor VIII (B-domain consists of 21 amino acids of the wild type B-domain) without any other modificationsin the amino acid sequence.
Turoktokog alfa je humani koagulacijski faktor VIII z odstranjeno domeno B (domena B obsega 21 aminokislin divjega tipa domene B), brez kakršnih koli drugih sprememb zaporedja aminokislin.
Turoctocog alfa is made by a method known as ‘recombinant DNA technology’: it is made by hamster cells into which a gene (DNA) has been introduced that make them able to produce it.
Turoktokog alfa se pridobiva s t. i. „tehnologijo rekombinantne DNK“: izdelajo ga celice hrčka, v katere so vstavili gen (DNK), s pomočjo katerega ga lahko tvorijo.
TURQUOISE-I: treatment-naïve or pegIFN + RBV-experienced with HIV-1 co-infection, without cirrhosis or with compensated cirrhosis
TURQUOISE-I – še nezdravljeni ali že zdravljeni s pegIFN + RBV, s sočasno okužbo s HIV-1, brez ciroze ali s kompenzirano cirozo
TURQUOISE-II was a randomised, global multicentre, open-label trial conducted exclusively in 380 genotype 1-infected subjects with compensated cirrhosis (Child-Pugh A) who were either treatment- naïve or did not achieve SVR with prior treatment with pegIFN/RBV.
Preskušanje TURQUOISE-II je bilo globalno multicentrično, randomizirano, odprto preskušanje izključno pri 380 preiskovancih, okuženih z genotipom 1, ki so imeli kompenzirano cirozo (Child- Pugh A) in še niso bili zdravljeni ali med predhodnim zdravljenjem s pegIFN/RBV niso dosegli SVR.
TURQUOISE-III: Clinical Trial of GT1b-Infected Subjects with Cirrhosis without RBV
TURQUOISE-III – klinično preskušanje pri preiskovancih, okuženih z GT1b in s cirozo, brez RBV
TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis
TURQUOISE-III – še nezdravljeni ali že zdravljeni s pegIFN + RBV, s kompenzirano cirozo
TURQUOISE-II– genotype 1, treatment-naïve or peginterferon+ribavirin-experienced subjects with compensated cirrhosis
TURQUOISE-II – še nezdravljeni ali že zdravljeni preiskovanci s peginterferonom+ribavirinom, z genotipom 1 in s cirozo
Tutti frutti flavour (contains sorbitol) Carmellose sodium Hydroxyethylcellulose
Aroma tutti frutti (vsebuje sorbitol) Natrijev karmelozat Hidroksietilceluloza
TVC-naïve(1)
Naivna TVC(1)
TW 36 visit and continued treatment with peginterferon alfa–2b + ribavirin for an additional 12 weeks, for a total treatment duration of 48 weeks.
TZ na "slep" način prešli na placebo ter nadaljevali zdravljenje s peginterferonom alfa-2b in ribavirinom dodatnih 12 tednov, tako da je celotno zdravljenje trajalo 48 tednov.
TW 48.
Zaznavna
Twelve double-blind, placebo-controlled, 6/8-week, fixed-dose studies have been conducted to investigate the short-term efficacy of vortioxetine in MDD in adults (including the elderly).
Da bi proučili kratkoročno učinkovitost vortioksetina pri odraslih bolnikih (vključno s starejšimi bolniki) z MDD, so izvedli dvanajst dvojno slepih, s placebom nadzorovanih, 6-/8-tedenskih študij s stalnimi odmerki.
Twelve months seizure freedom
Dvanajst mesecev brez epileptičnega napada
Twelve months seizure freedom
Podtip epileptičnega napada (6 mesecev brez epileptičnega napada – populacija PP)
Twelve months seizure freedom
Šest mesecev brez epileptičnega napada
Twelve of the fifteen patients died within 30 days of the last dose of necitumumab and had comorbid conditions including history of coronary artery disease (n=3), hypomagnesemia (n=4), chronic obstructive pulmonary disease (n=7), and hypertension (n=5).
Dvanajst od petnajstih bolnikov je umrlo v 30 dneh po zadnjem odmerku necitumumaba in je imelo sočasna obolenja, vključno s koronarno arterijsko boleznijo (n = 3), hipomagneziemijo (n = 4), kronično obstruktivno pljučno boleznijo (n = 7) in hipertenzijo (n = 5) v anamnezi.
Twenty (21 %) of 97 children had a > 15 percentile decrease in height percentile, of whom 10 of the 20 children had a > 30 percentile decrease in their height percentile from the start of treatment to the end of long-term follow-up (up to 5 years).
97 otrok je imelo zmanjšanje telesne višine za > 15 percentilov, 10 od teh 20 otrok pa je imelo zmanjšanje telesne višine za > 30 percentilov od začetka zdravljenja do konca dolgoročnega spremljanja bolnikov (do 5 let).
Twenty cats naturally infested with lungworm were treated with Broadline.
Z zdravilom Broadline so zdravili 20 mačk naravno okuženih s pljučnim črvom.
Twenty five percent (15 out of 60) of the overall patient population was adult (>18 years) at baseline.
Petindvajset odstotkov (15 od 60) celokupne populacije bolnikov je bilo ob izhodišču odraslih (> 18 let).